Centauri Therapeutics raises €27.6M Series A round
16 February 2022· Nether Alderley, United Kingdom· health, biotech, b2b, b2g, deep_hardware
The funding will support the continued advancement of the company's antimicrobial resistance research and development, using its proprietary Alphamer platform to identify and progress novel antibacterial candidates through first-in-human trials.
“We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections. This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset.”
Investors
LeadBoehringer Ingelheim Venture Fund
Also participating
Evotec SENovo Holdings REPAIR Impact FundAnimatrix Founders LLPLAK Holdings LLPKent Life Science LLPWren Capital
About Centauri Therapeutics
Headquarters
Nether Alderley, United Kingdom
Founded
2014
Team Size
21–50
Sectors
healthbiotechb2bb2gdeep_hardware